Trans-Hit Biomarkers - Regulatory Services

By: Trans-hit Biomarkers  09-12-2011

Too often early R&D programs do not take into consideration the future regulatory and clinical requirements for getting a Biomarker to market. Based on the regulatory path that we will define for you, we can help you optimize each step of your research and development plan from concept to marketing strategy. In this way, you will have a more accurate estimate of your technical and financial needs.

Trans-Hit Biomarkers can assist you with designing and planning the regulatory strategy for all international markets.  Our team has extensive experience with:

  • U.S. FDA filings of In Vitro Diagnostics (Pre-IDE Meeting, IDE, IVD, IVDMIA)
  • Regulatory filings in Europe: technical documents for CE Mark, liaison with notified bodies, and developing and submitting CE Mark filings for EU
  • Regulatory filings in Canada, Japan and Australia

No matter the size of your institution or company, private or public, we tailor our services to your needs, providing you with customized services. Our corporate goal is to develop long-term relationships and commitments with our clients and to provide high-quality, comprehensive services and expert support.

Trans-Hit Biomarkers offers a selection of services to pick and choose from to fit your individual development needs.

  • Regulatory planning and design
  • Full regulatory support, preparing dossiers and acting as a liaison with regulatory authorities
  • Hourly regulatory consulting for “simple” questions or presentations
  • Quality System Management planning
  • Standard Operating Procedure (SOP) development
  • Organizational gap analysis
  • Marketing strategy and planning, based on regulatory path
  • Labeling, packaging and advertising development within the regulatory framework

Contact Trans-hit Biomarkers

Email - none provided

Print this page

Other products and services from Trans-hit Biomarkers


Trans-Hit Biomarkers - Unique services to TTOs and their scientists developing new biomarkers and diagnostic technologies

Our expertise in helping biomarker scientists to advance their biomarkers to the market is widely recognized by many well-known TTOs and key industrial players in the biomarker domain. At Trans-Hit Biomarkers we know the challenges you face in taking your newly discovered biomarker through validation and eventually to a commercialized product.


Trans-Hit Biomarkers - Access To Animal Models

In addition, selected preclinical CRO partners have extensive knowledge and expertise in their respective fields of specialization, offering Trans-Hit Biomarkers and its clients the ability to evaluate the pertinence of their biomarkers.


Trans-Hit Biomarkers - Proteome-Hit

By combining Trans-hit Biomarkers’ access to large high-quality biospecimen collections with Caprion’s high-throughput and quantitative multiplexed mass spectrometry assays, Proteome-Hit turns the usually expensive and time-consuming clinical validation route into a fast, cost-effective and robust process.


Trans-Hit Biomarkers - Prospective Biobanking Services

Trans-Hit Biomarkers will take care of the selection, set-up and monitoring of investigator sites when multicenter prospective studies are needed for the clinical validation of new biomarkers, maintaining high-quality standards for biospecimen sampling, shipping and storage. Trans-Hit Biomarkers can help you decide which path is right for your clinical and regulatory plans, as well as help you to find retrospective samples to fit your needs.


Trans-Hit Biomarkers - Access To Human Biospecimen Collections

Assuming sample collections are of good quality and that the scientific, legal and regulatory challenges have been overcome, sample-based research should ultimately lead to the discovery and validation of new biomarkers for predictive, prognostic, surrogate and efficacy diagnostic tests.


Trans-Hit Biomarkers - ImaProteome

MALDI-Imaging Mass Spectrometry technology developed by ImaBiotech allows to generate molecular images and to quantify the distribution of molecules in complex samples such as organs, tissues and biopsies, without labeling, extraction/purification and degradation. Via automation and data processing, molecular maps of molecules can be easily generated from tissue sections collected from patients with cancer, CNS diseases, and many other diseases.